Komipharm International Co Ltd

Overview

Komipharm International Co Ltd (Komipharm), formerly KOMI of Korea Microbiological Laboratories Ltd offers pharmaceutical and animal health products. The company’s product pipeline includes PAX-1-001, a non-opioid drug candidate designed to treat cancer pain; PAX-1-002 for treating brain cancer; PAX-1-004 against gallbladder, prostate cancer and multiple myeloma; KML001 an oral drug used for the treatment of prostate, solid, biliary tract, lung and liver cancer and malignant lymphoma; PAX-1-003, to treat lung to brain metastases, head and neck cancer, metastatic melanoma, osteosarcoma and soft tissue cancer. It also develops vaccines and medical products for treating fever, pain, skin problems and other diseases in animals. Komipharm works in partnership with other pharmaceutical companies worldwide to develop its pipeline products. The company operates production facilities in Australia and South Korea. Komipharm is headquartered in Siheung, South Korea
Key Stats
Address
17, Gyeongje-ro, Siheung-Si, SIHEUNG, South Korea
Headquarters

South Korea

Contact

82 31 4982121

No of Employees

155

Industry

Pharmaceuticals and Healthcare

Ticker Symbol & Exchange​

041960 [KOSDAQ]

Revenue (2020)

$32 m

5% (2020 vs 2019)
Net Income (2020)

$-2 m

89.1% (2020 vs 2019)
Net Profit Margin

-8 %

87.4% (2020 vs 2019)
Market Cap *

$582 m

EPS *

$-0

  *Note: Ratios based on the share price as of 8-September-2021, in absolute numbers and US$.

Peer Comparison

Key Parameters Komipharm International Co LtdDaihan Pharm Co LtdCtcbio IncEagle Veterinary Technology Co Ltd
Key Information
Headquarters South Korea South Korea South Korea South Korea
Headquarter City SIHEUNG SEOUL HONGCHEON YESAN
Headquarter State/Province - - - -
No. of Employees 155 685 258 114
Entity Type Public Public Public Public

Products & Services

Komipharma operates as a provider of pharmaceutical and animal health drugs. Key products offered by the company include the following:

Products
  • Pipeline Portfolio
  • PAX-1-001 -Non-Opioid Cancer Pain
  • PAX-1-002 - Brain Cancer
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
Key Financial Charts
Sales Growth
Operating Margin
Net Income Growth
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets

Employees

Name Position Board Since Age Biography
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
1972 Incorporation/Establishment The company was founded.

Locations


Komipharm International America Inc
Kominox Usa Inc
Komipharm International Australia Pty Ltd

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
12 Mar 2020 Komipharm International Co Ltd Enters Phase II/III Clinical Trial Agreement with Novotech Australia Pty Ltd for PAX-1 (GDCT0381657) Contract Service Agreement Komipharm International Co Ltd Novotech Australia Pty Ltd
06 Mar 2020 Komipharm International Enters into Agreement with Novotech for Covid-19 Partnership Novotech Australia Pty Ltd; Komipharm International Co Ltd
06 Mar 2020 Novotech Enters into Agreement with Komipharm for Covid-19 Partnership Komipharm International Co Ltd; Novotech Australia Pty Ltd
12 Jan 2017 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
28 Dec 2011 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
20 Dec 2011 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit